Yozma Group Korea

Yozma Group Korea, established in 2015 and headquartered in Seoul, South Korea, is a venture capital firm focused on investing in early-stage companies. The firm targets a diverse array of sectors, including biotechnology, information and communications technology, media, edutech, and electronics, as well as other innovative technology areas. By identifying and supporting promising startups, Yozma Group Korea aims to foster growth and innovation within these dynamic industries.

Wonjae Lee

Head of Asia Pacific of Yozma Group Asia and CEO of Yozma Group Korea

6 past transactions

Betterteem AI®

Venture Round in 2022
Betterteem is a predictive and prescriptive AI platform that enables businesses to predict unwanted employee resignations with AI. Betterteem's AI-driven prediction resulted in an 18% increase in employee retention and a 41% increase in productivity in 2023, saving clients over US$18 million in backfill hiring costs and lost productivity.

INGRADIENT

Seed Round in 2021
INGRADIENT is a medical AI data labeling company focused on enhancing the efficiency and accuracy of data processing for healthcare professionals. Its primary product, MediLabel, is a software platform designed to label large-scale medical images quickly by learning user labeling patterns. This innovative approach not only reduces data processing time but also improves the precision of labeling outputs. By streamlining the labeling process, INGRADIENT enables doctors and researchers to save both time and costs, ultimately supporting better decision-making in medical settings.

CK Regeon

Series B in 2021
CK Regeon is a biotechnology company focused on improving human health through the development of innovative drugs. The company specializes in creating small molecules and peptides aimed at treating metabolic disorders, including obesity, diabetes, and non-alcoholic steatohepatitis. Additionally, CK Regeon is dedicated to promoting hair growth and enhancing wound healing, utilizing target-specific compounds that enable medical practitioners to effectively address these health issues.

HashBrand

Seed Round in 2020
HashBrand is a blockchain technology that provides an activation system.

Mirae SCI

Venture Round in 2018
Mirae SCI is A Global Company Dreaming of a New Future A company that creates a pleasant world through challenges and innovation. .

Syntekabio

Series B in 2018
Syntekabio, Inc. is a bioinformatics company based in Daejeon, South Korea, founded in 2009. It specializes in managing and analyzing genomic data through advanced algorithms and artificial intelligence. The company develops personal genome maps that serve as comprehensive resources for disease prevention and tailored drug development. Additionally, it offers genome data integration services and operates a supercomputer known as MAHA, which enhances data processing efficiency for genome-based diagnostics. Syntekabio also focuses on collecting and integrating decrypted whole genome data for various applications, including the analysis of rare diseases and genetic relationships, by sequencing blood samples from diverse populations worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.